featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have announced a collaboration to “discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases” focused on ocular and central nervous system (CNS) indications. It is understood that Regeneron will pay a $400 million upfront payment to Alnylam and will […]

Read full story
Featured

The EU Clinical Trials Register (EUCTR) indicates that the compliance with the EU rules “have been poor overall”

A new automated tool, the “EU TrialsTracker”, has been launched by several academic researchers working at the Evidence-Based Medicine Data Lab, University of Oxford, UK.  The tool provides an automated software algorithm designed to identify commercial and non-commercial clinical trial sponsors with the best and worst record for sharing trial results.  The underlying premise is […]

Read full story
Research

Optogenetics research uses medium-wavelength cone opsin to re-engineer retinal ganglion cells for retinitis pigmentosa

Researchers at the University of Berkeley have reported that the vertebrate medium wavelength cone opsin (MW-opsin) may be used to overcomes limitations to support vision in dim light in a mouse model for retinitis pigmentosa (RP).  The study will be used to develop optogenetic therapy to overcome downstream retinal neurons where rod photoreceptors may have […]

Read full story
Introduction

April 16th, 2019: “EURETINA-Brief” Issue No. 190

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”.  EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Market/Novel Tech

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story
Featured

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Latest News

Book Review